HYPAQUE-M,75%
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Nov 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYPAQUE-M 75% is an injectable contrast medium approved in 1955 by GE HealthCare, used primarily for radiographic imaging procedures. The product is a diagnostic agent that enhances visualization in medical imaging, particularly for angiography and other interventional procedures. It represents a legacy injectable diagnostic modality now facing lifecycle maturity.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling a consolidating team focused on margin protection rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HYPAQUE-M 75% offers limited career growth opportunities given its mature, LOE-approaching status and zero linked job openings. Roles on this product emphasize operational excellence, compliance, and margin protection in a declining or stable market rather than innovation or expansion.
Supply Chain ManagerRegulatory Affairs Specialist
Worked on HYPAQUE-M,75% at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.